Calliditas Therapeutics AB (publ)

OM:CALTX 株式レポート

時価総額：SEK 11.2b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Calliditas Therapeutics マネジメント

マネジメント 基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Renee Aguiar-Lucander

最高経営責任者

SEK 18.4m

報酬総額

CEO給与比率36.6%
CEO在任期間7.4yrs
CEOの所有権n/a
経営陣の平均在職期間3.6yrs
取締役会の平均在任期間less than a year

経営陣の近況

Recent updates

Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results

Feb 24
Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results

Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Jan 12
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost

Dec 22
Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost

Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?

Sep 22
Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?

What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today

Aug 19
What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today

Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%

May 26
Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%

Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?

Feb 24
Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?

Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Nov 25
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%

Aug 24
Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%

Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?

Aug 03
Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?

CEO報酬分析

Calliditas Therapeutics の収益と比較して、Renee Aguiar-Lucander の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-SEK 480m

Mar 31 2024n/an/a

-SEK 525m

Dec 31 2023SEK 18mSEK 7m

-SEK 466m

Sep 30 2023n/an/a

-SEK 451m

Jun 30 2023n/an/a

-SEK 292m

Mar 31 2023n/an/a

-SEK 393m

Dec 31 2022SEK 13mSEK 6m

-SEK 412m

Sep 30 2022n/an/a

-SEK 628m

Jun 30 2022n/an/a

-SEK 608m

Mar 31 2022n/an/a

-SEK 576m

Dec 31 2021SEK 11mSEK 5m

-SEK 500m

Sep 30 2021n/an/a

-SEK 452m

Jun 30 2021n/an/a

-SEK 600m

Mar 31 2021n/an/a

-SEK 501m

Dec 31 2020SEK 7mSEK 3m

-SEK 433m

Sep 30 2020n/an/a

-SEK 286m

Jun 30 2020n/an/a

-SEK 198m

Mar 31 2020n/an/a

-SEK 54m

Dec 31 2019SEK 4mSEK 3m

-SEK 33m

Sep 30 2019n/an/a

-SEK 54m

Jun 30 2019n/an/a

-SEK 35m

Mar 31 2019n/an/a

-SEK 136m

Dec 31 2018SEK 4mSEK 2m

-SEK 132m

報酬と市場: Reneeの 総報酬 ($USD 1.77M ) は、 Swedish市場 ($USD 754.57K ) の同規模の企業の平均を上回っています。

報酬と収益: Reneeの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Renee Aguiar-Lucander (62 yo)

7.4yrs

在職期間

SEK 18,367,000

報酬

Ms. Renee Aguiar-Lucander serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief Executive Officer of Calliditas Therapeutics AB (publ) since May 2017. Prior to joining...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Renee Aguiar-Lucander
Chief Executive Officer7.4yrsSEK 18.37mデータなし
Fredrik Johansson
Chief Financial Officer7.2yrsデータなし0%
SEK 0
Lars Stubberud
Vice President of Technical Operations1.8yrsデータなしデータなし
Asa Hillsten
Head of IR & Sustainability1.8yrsデータなしデータなし
Brian Gorman
Group General Counsel1.8yrsデータなしデータなし
Sandra Frithiof
Vice President of Human Resources4.8yrsデータなしデータなし
Ann-Kristin Myde
Head of Clinical Development & VP of Project Management7.8yrsデータなしデータなし
Richard Philipson
Chief Medical Officer4.3yrsデータなしデータなし
Teona Johnson
Head of US Marketing3.6yrsデータなしデータなし
David Ferraro
Head of US Sales3.6yrsデータなしデータなし
Monika Tornsen
President of North Americaless than a yearデータなしデータなし
Christopher Ngai
Vice President of Market Accessno dataデータなしデータなし

3.6yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: CALTXの経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Yoshikazu Aoki
Non-Executive Directorless than a yearデータなしデータなし
Mark Hensley
Chairmanless than a yearデータなしデータなし
Jonathan Barratt
Member of Scientific Advisory Boardno dataデータなしデータなし
Jürgen Floege
Member of Scientific Advisory Boardno dataデータなしデータなし
Richard Lafayette
Member of Scientific Advisory Boardno dataデータなしデータなし
Brad Rovin
Member of Scientific Advisory Boardno dataデータなしデータなし
Vladimir Tesar
Member of Scientific Advisory Boardno dataデータなしデータなし
Hérnan Trimarchi
Member of Scientific Advisory Boardno dataデータなしデータなし
Masaya Etoh
Non-Executive Directorless than a yearデータなしデータなし
Heather Reich
Member of Scientific Advisory Boardno dataデータなしデータなし
Hong Zhang
Member of Scientific Advisory Boardno dataデータなしデータなし

0.08yrs

平均在職期間

経験豊富なボード: CALTXの 取締役会 は 経験豊富 ではない ( 0.1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。